The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Clinical · Special populations · continued

Coming back to: Renal impairment: what the labelling says about dose posts 31–35

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

TK
t.kulkarniTL3Regular23 Jan 2025#31
MSaarinen, post #23: Worth separating two things that post #19 runs together. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

post #30 answers the question as asked. The question underneath it is different.

Older adults: sarcopenia risk is higher, polypharmacy is common, and the clinical trials did not enroll many people over 75. Extrapolating to very old people is extrapolating beyond the data.

0 likes in reply to #23 18mo
GO
g.oyelaranTL2 Moderator27 Jan 2025#32

On post #28 — agreed on the reasoning, with one qualification.

Pregnancy and planning: these compounds are not approved for use in pregnancy. Planning windows (how long to wait before attempting pregnancy) are not formally established. Conservative approaches wait several months to allow clearance.

0 likes 18mo
IL
integrator_logTL3Regular31 Jan 2025 · edited#33

Adolescents: a distinct evidence base exists. The compounds are not approved for routine adolescent obesity but are being studied. Adolescent physiology and psychology differ from adults' in ways that matter for this medication class.

7 likes 18mo
JP
j.palaciosTL2 Moderator3 Feb 2025#34

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

17 likes 18mo
V
VPoulsenTL3Regular7 Feb 2025#35
t.lindqvist, post #22: Pancreatitis history: the compounds can rarely trigger pancreatitis. A history of pancreatitis makes monitoring for recurrence more important during titration. Go to post

Renal impairment: the compounds are cleared renally to some degree. Dose adjustments might be needed in severe renal impairment. Consulting with a clinician familiar with renal dosing is prudent.

0 likes in reply to #22 18mo

Suggested topics

TopicParticipantsRepliesViewsActivity
Older adults, sarcopenia risk, and the trade-off nobody quantifies
Older adults, sarcopenia risk, and the trade-off nobody quantifies — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published…
VJSATYAJR+103 109 12k 5mo
Hepatic impairment and the absence of data — a second dataset
On the subject in the title: Hepatic impairment and the absence of data — a second dataset Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in…
ACMODN 2 4.3k 4mo
People with a low starting BMI: where the evidence stops
Posting this under the heading it deserves: People with a low starting BMI: where the evidence stops Everything below is what sits behind that. Asking about a population rather than about a person. The…
VFJDSOAWAW+23 27 5.8k 19mo
Type 1 diabetes: off-label use and the evidence gap — what changed since
Type 1 diabetes: off-label use and the evidence gap — what changed since — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The…
SOKRZSNTSD+68 77 31k 20mo
Coming back to: Bariatric surgery history: altered anatomy, altered expectations
Bariatric surgery history: altered anatomy, altered expectations Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
GADSST 2 38k 15mo

Related topics — sharing the tags chronic kidney disease, adolescents, disordered eating

TopicParticipantsRepliesViewsActivity
PCOS and metabolic overlap: what is and is not studied
On the subject in the title: PCOS and metabolic overlap: what is and is not studied Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in this…
SGPGBST 3 6.6k 1d
Food noise reducing and the disorientation that can follow
Posting this under the heading it deserves: Food noise reducing and the disorientation that can follow Everything below is what sits behind that. General question, not a request for advice about my own care —…
JWKACCJFV+40 45 8.9k 20mo
Athletes in weight-category sports: a different risk calculus — a second dataset
On the subject in the title: Athletes in weight-category sports: a different risk calculus — a second dataset Working notes rather than a conclusion. General question, not a request for advice about my own…
NNRFKKFFSH+37 41 16k 20mo
Mood changes: monitoring, and when to involve a professional
Mood changes: monitoring, and when to involve a professional — setting out what I have, and where I think it stops being reliable. General question, not a request for advice about my own care — I know the…
CGALGV 2 362 13mo
Hepatic impairment and the absence of data
Hepatic impairment and the absence of data — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published trials in this class mostly…
MAMLDYAWCC+30 35 32k 10mo